Experts speak about external innovation and collaboration

Dr. Faiz Ahmad is a Professor and the Head of Centre for Advanced and Functional Materials at the Universiti Teknologi PETRONAS (UTP), a leading private university in Malaysia established in...

The Materials Science Institute of Mulhouse (IS2M) leads a multidisciplinary research in materials science with high-level expertise in chemistry and physics of surfaces and interfaces and in the field of...

Aitiip Technology Centre is a private foundation whose patronage is composed of large companies in the plastic processing sector. Thanks to Inospin, the Aitiip managed to set a collaboration with...

Lincoln Agritech, a research and development company owned by Lincoln University (New Zealand), has established a collaboration with a global FMCG corporation through the intermediation of Inospin. Dr Rob Kelly,...

Janssen PMP is a division of Janssen Pharmaceutica (Johnson & Johnson) specialized on postharvest treatment (shelf life of fruits and vegetables) and microbial control (plastics, anti-fooling and wood protection). With...

Essilor is the world's leading ophthalmic optics company with Headquarters in France. The company designs, manufactures and markets lenses to improve and protect eyesight. Dr. Feuillade, explains how Essilor collaborates...

Interview with Jules Roelofs, Global Innovation Manager at Holland Colours, Holland Colours is a multinational company headquartered in the Netherlands. The company develops liquid and solid colorants and additives for...

Dr Bansal explains how her group, The Liver Lab at the University of Twente (NL) foresees collaborating with industry to make an impact on the society and reviews the critical...

Dr Pastoureau explains how collaborating with academia and start-ups is essential for Drug discovery in Big Pharma. Dr. Pastoureau also comments on his experience with Inospin and how the platform...

Dr Palmer explains how he was involved as a consultant on pharmaceutical drug development, interpretation of experimental results, perform research experiments and associated issues.

Dr Bleier explains why for him working with Industry is a critical step to advancing investigator-initiated work to broader patient care.

Michael Donabedian presents how Vetoquinol collaborates with Academic partners

External innovation and collaboration with Academia

In response to the dual challenges of increasingly risky target portfolios and realignment of traditional pharmaceutical company resources away from early-phase research and development (R&D), research groups have sought to...